Choi J, et al. – Researchers conducted a post–commercialization study which indicated that LDL cholesterol (LDLC) decreased from 115 to 68 mg/dl (39%) on alirocumab (ALI) 75 mg with mean follow–up of 49 weeks, and from 165 to 70 mg/dl (59%) on ALI–evolocumab (EVO) over 37 weeks, p < .0001 for both. Adverse events were minimal and tolerable in patients with heterozygous familial hypercholesterolemia (HeFH) and/or cardiovascular disease (CVD). In addition, ALI and EVO represent paradigm shifts in LDLC lowering.